The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Advanced Accelerator Applications/Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
 
Jonathan R. Strosberg
Consulting or Advisory Role - Novartis
Speakers' Bureau - Ipsen; Lexicon
Research Funding - Novartis
 
Martyn E Caplin
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Ipsen; Sirtex Medical
Speakers' Bureau - Advanced Accelerator Applications/Novartis; Ipsen; Pfizer; Sirtex Medical
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Ipsen (Inst)
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - Acrotech Biopharma; Advanced Accelerator Applications/Novartis; Ipsen; Lexicon; Sun Pharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Brahms (Inst); Ipsen (Inst); Lexicon (Inst); Xencor (Inst)
 
Philippe B Ruszniewski
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Ipsen; Isotopen Technologien; Novartis
Research Funding - Advanced Accelerator Applications/Novartis; Ipsen; Isotopen Technologien
Travel, Accommodations, Expenses - Ipsen
 
Lisa Bodei
Research Funding - Advanced Accelerator Applications/Novartis
(OPTIONAL) Uncompensated Relationships - Advanced Accelerator Applications/Novartis; Clovis Oncology; Curium Pharma; IBA; Isotopen Technologien
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
Erik Mittra
Honoraria - Advanced Accelerator Applications/Novartis; Curium Pharma
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Ipsen
Research Funding - Advanced Accelerator Applications/Novartis; Nordic Nanovector
 
Edward M. Wolin
Consulting or Advisory Role - Advanced Accelerator Applications; Lexicon; Progenics
 
James C. Yao
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Chiasma; Crinetics Pharmaceuticals; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications/Novartis
 
Marianne E Pavel
Honoraria - Advanced Accelerator Applications; Boehringer Ingelheim; Hutchison MediPharma; IPSEN; Riemser
Consulting or Advisory Role - Advanced Accelerator Applications; IPSEN
Travel, Accommodations, Expenses - Hutchison MediPharma; IPSEN
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; EUSA Pharma; Genzyme; IPSEN; Janssen-Cilag; Lexicon; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Ettore Seregni
No Relationships to Disclose
 
Hugo Duarte
No Relationships to Disclose
 
Germo Gericke
No Relationships to Disclose
 
Amy Bartalotta
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Arnaud Demange
Employment - Advanced Accelerator Applications/Novartis
Stock and Other Ownership Interests - Advanced Accelerator Applications/Novartis
 
Sakir Mutevelic
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
 
Eric Krenning
Employment - Cyclotron Rotterdam
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Merck; Roche
Patents, Royalties, Other Intellectual Property - Advanced Accelerator Applications/Novartis
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis
(OPTIONAL) Uncompensated Relationships - Advanced Accelerator Applications/Novartis